STOCK TITAN

Mirum (MIRM) director Lon Cardon granted RSUs and options at $101 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Mirum Pharmaceuticals director Lon Cardon received new equity awards as part of his compensation. He was granted 1,980 restricted stock units, each representing the right to receive one share of common stock, and 3,772 stock options with an exercise price of $101.00 per share.

Both the RSUs and options vest on the first anniversary of the June 15, 2026 grant date, and in any event will be fully vested by the company’s 2027 annual stockholder meeting. After these awards, Cardon directly holds 1,980 RSUs and 3,772 options, with no shares bought or sold in this filing.

Positive

  • None.

Negative

  • None.
Insider Cardon Lon
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,772 $0.00 --
Grant/Award Restricted Stock Units 1,980 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,772 shares (Direct, null); Restricted Stock Units — 1,980 shares (Direct, null)
Footnotes (1)
  1. The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
RSU grant 1,980 units Restricted stock units granted June 15, 2026
Option grant 3,772 options Stock options granted June 15, 2026
Option exercise price $101.00 per share Stock option strike price
Option expiration June 14, 2036 Option expiration date
Restricted Stock Units financial
"He was granted 1,980 restricted stock units, each representing the right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options financial
"and 3,772 stock options with an exercise price of $101.00 per share"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"3,772 stock options with an exercise price of $101.00 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"Both the RSUs and options vest on the first anniversary of the June 15, 2026 grant date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual stockholder meeting financial
"and in any event will be fully vested by the company’s 2027 annual stockholder meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cardon Lon

(Last)(First)(Middle)
C/O MIRUM PHARMACEUTICALS, INC.
989 E HILLSDALE BLVD., SUITE 300

(Street)
FOSTER CITY CALIFORNIA 94404

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$10106/15/2026A3,772 (1)06/14/2036Common Stock3,772$03,772D
Restricted Stock Units(2)06/15/2026A1,980 (2) (2)Common Stock1,980$01,980D
Explanation of Responses:
1. The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
/s/ Doug Sheehy, Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Mirum Pharmaceuticals (MIRM) director Lon Cardon receive?

Lon Cardon received grants of RSUs and stock options. He was awarded 1,980 restricted stock units and 3,772 stock options, each tied to common shares, as part of his director compensation, with future vesting based on time and the 2027 annual meeting.

When do Lon Cardon’s new Mirum (MIRM) RSUs and options vest?

The RSUs and options primarily vest after one year. Both the 1,980 RSUs and 3,772 options vest on the first anniversary of the June 15, 2026 grant date, or will in any case be fully vested by Mirum’s 2027 annual stockholder meeting.

What is the exercise price of Lon Cardon’s Mirum (MIRM) stock options?

The granted stock options have a set exercise price. Cardon received 3,772 stock options with an exercise price of $101.00 per share, allowing him to purchase Mirum common stock at that price once the options vest and are exercisable.

Did Lon Cardon buy or sell any Mirum (MIRM) shares in this Form 4?

No open-market buys or sells occurred in this filing. The Form 4 only reports compensation-related grants: 1,980 restricted stock units and 3,772 stock options. These are awards, not market transactions, and do not reflect discretionary buying or selling.

How many Mirum (MIRM) awards does Lon Cardon hold after these grants?

The filing shows Cardon’s derivative holdings from these awards. After the June 15, 2026 grants, he directly holds 1,980 restricted stock units and 3,772 stock options, all tied to Mirum common shares, with vesting linked to time and the 2027 annual meeting.